GLP-1 receptor agonists are extending beyond diabetes and obesity into multi-target combinations, oral small molecules, and potential 2025 FDA approvals for chronic kidney disease, heart failure, and liver disease. CagriSema heads toward a late 2025 filing while orforglipron's Phase III trial…
GLP-1 receptor agonists are no longer best described as diabetes and obesity drugs. The class is advancing into multi-target receptor combinations, oral small-molecule formats, and new regulatory territory, with a cluster of milestones expected in 2025. The U.S. Food and Drug Administration could approve GLP-1 receptor agonists for chronic kidney disease, heart failure, or specific liver diseases in 2025. CagriSema cagrilintide/semaglutide is expected to file for approval in late 2025, and orforglipron , a small-molecule oral GLP-1 receptor agonist candidate, is expected to complete its Phase III trial in 2025.
The multi-target direction is already visible in approved and late-stage products. Three multi-target receptor combinations are listed for Phase II/III or approved therapeutics: GLP-1R/GIPR, GLP-1R/GCGR, and GLP-1R/GIPR/GCGR. Tirzepatide , Eli Lilly's GLP-1R/GIPR dual agonist, anchors the category commercially. Behind it sit candidates that pair GLP-1 receptor agonism with glucagon receptor stimulation, and triple agonists that engage all three receptors at once.
The shift is mechanistically coherent. GLP-1 receptors are part of the G protein-coupled receptor family and are broadly expressed across various human cell types; activation regulates blood sugar levels, suppresses appetite, slows gastric emptying, and promotes satiety. Multi-target design extends those effects by engaging the GIP and glucagon receptors, which have their own tissue distributions and metabolic roles. The receptor pharmacology is catalogued in the IUPHAR/BPS Guide to Pharmacology, and the trial record is indexed at ClinicalTrials.gov, operated by the U.S. National Library of Medicine and the National Institutes of Health.
CagriSema combines the peptides cagrilintide and semaglutide in a single injectable. The combination has shown greater weight loss than Wegovy semaglutide , and a filing for approval is expected in late 2025. The claim of superior weight loss has been presented without quantitative results or statistical detail; the size of the gap between the two regimens has not been specified. Wegovy is already established in the obesity market, and a fixed two-peptide combination needs a clearly quantified advantage to justify the added complexity of a second active ingredient.
Orforglipron takes a different route. It is not a peptide at all, but a small-molecule oral GLP-1 receptor agonist whose Phase III trial is expected to complete in 2025. If it succeeds, it could offer a lower-cost oral alternative to injectable GLP-1 therapies, a prospect that consumer drug pricing services such as GoodRx track closely. The lower-cost scenario is conditional on meeting Phase III endpoints, and the trial outcome is not yet known.
The oral route is the harder delivery problem. Injectable peptides reach the bloodstream intact, while oral peptides must survive the gut and cross the intestinal wall. The one marketed oral peptide in this class, oral semaglutide for type 2 diabetes, is co-formulated with SNAC, a permeation enhancer that began being used in clinical trials in the late 1990s for oral formulations containing poorly permeable active compounds. CagriSema and orforglipron therefore represent two competing answers to the delivery question: an injectable combination therapy versus an oral small molecule that bypasses peptide delivery problems entirely.
The 2025 regulatory prospect is not a single filing. The FDA could approve GLP-1 receptor agonists for chronic kidney disease, heart failure, or specific liver diseases, three organ systems where the class has accumulated outcome data. The mechanism of action gives the drugs plausible traction in each: renal protection, cardiovascular effects, and effects on metabolic dysfunction-associated liver disease.
The scope matters. Approvals in these indications would not simply add label lines to existing drugs. They would reposition the class as organ-protective therapy and could extend treatment to patients without diabetes and, in some cases, without obesity, the populations that drove the original approvals. The prescribing base would shift as well: nephrologists, cardiologists, and hepatologists, not only endocrinologists, would become the primary prescribers.
The key word is could. The 2025 approval possibility is a trend projection, not a confirmed regulatory action, and no specific product or indication has been locked in. Which chronic kidney disease, heart failure, and liver disease indications the FDA will actually consider in 2025 remains an open question.
The biology starts with GLP-1, a hormone that activates receptors in the G protein-coupled receptor family. These receptors are broadly expressed across various human cell types. Activation regulates blood sugar levels, suppresses appetite, slows gastric emptying, and promotes satiety. Native GLP-1, however, has a plasma half-life of about 1.5 minutes, which makes it unsuitable for direct clinical use because the enzyme DPP-4 rapidly cleaves it.
The first fix was at the N-terminus. Replacement of the second N-terminal amino acid, Ala8, prevents DPP-4 degradation. That single substitution appears across the class, in exenatide, lixisenatide, semaglutide, dulaglutide, and albiglutide. DPP-4 resistance alone does not make a long-acting drug, since the peptide still clears through the kidneys. The second fix changed the molecule's size and lipophilicity.
The strategies diverge from there. Albiglutide is a DPP-4-resistant GLP-1 dimer fused to human albumin; the fusion extends its half-life and permits once-weekly dosing. The lipidated analogues semaglutide and liraglutide have in vivo half-lives of hours to days, compared with minutes for native GLP-1. PEGylation prolongs half-life and enhances bioavailability: the exendin-4 analogue ExC39 modified with a 20 kDa PEG, ExC39PEG20 kDa, showed a blood half-life approximately 10 times longer than ExC39. Fusing GLP-1 to albumin or other proteins can also help it escape lysosomal degradation, a separate clearance route for internalized peptides. Work published in 2023 extended the fusion concept with a novel Fc fusion protein that acts as a dual GLP-1 and gastric inhibitory polypeptide receptor agonist. The newer multi-target peptides inherit all of these engineering tools.
Single-receptor GLP-1 therapy has a documented ceiling. GLP-1 receptor agonists may show plateauing efficacy at higher doses in diabetic patients, and if maximum tolerated GLP-1 receptor activation stops delivering additional weight loss or glycemic control, the remaining gains must come from other pathways.
The three combinations in late-stage development map onto that logic. GLP-1R/GIPR dual agonism, the tirzepatide configuration, pairs the two incretin hormones. GLP-1R/GCGR dual agonism adds glucagon receptor stimulation to the incretin signal. The GLP-1R/GIPR/GCGR triple configuration combines all three pathways. Each added receptor has its own tissue distribution and metabolic effects, the basis for the expectation that combining GLP-1 receptor agonists with glucagon or glucose-dependent insulinotropic polypeptide can achieve greater weight reduction and metabolic benefits than GLP-1 alone. That expectation has been met for one pair: tirzepatide is approved. For the glucagon-containing pairs and the triple, the comparative evidence is still in Phase II/III.
What the record does not yet show is which combination wins. The Phase II/III multi-target therapeutics table is referenced to ClinicalTrials.gov but is not reproduced in the material reviewed here, and head-to-head comparisons against tirzepatide have not been published in quantitative detail. The choice between GIP, glucagon, or both will determine how the multi-target segment splits. It will also determine manufacturing demand, because the glucagon-containing and triple candidates are longer and more complex sequences than the first-generation agonists.
Tirzepatide is the test case for whether these longer peptides can be made at commercial scale. Michael O. Frederick of Eli Lilly reported kilogram-scale GMP manufacture of tirzepatide in 2021, using a hybrid approach that combined solid-phase peptide synthesis SPPS with liquid-phase peptide synthesis LPPS and continuous manufacturing.
The process design reflects the limits of each method. Stepwise SPPS is efficient for shorter sequences but accumulates errors on long chains. Solution-phase conjugation of large fragments avoids part of that accumulation but requires each fragment to be made and purified first. Frederick's route split tirzepatide into four peptide fragments, synthesized them separately, and conjugated them stepwise, with nanofiltration between steps and online HPLC analysis to track the process in real time. The reported outcome: an overall yield of 46% for crude tirzepatide, with crude purity greater than 70%.
Those two figures describe the crude product coming out of the synthesis train, before chromatographic purification to drug substance. Final purity is a separate checkpoint. Third-party lab purity tests on file at Peptide Atlas show a highest observed purity of 99.864% for tirzepatide across 4 tests and 99.979% for semaglutide across 8 tests; both measure finished product, reached only after purification steps that the crude yield and purity figures do not include. The manufacturing question for any new multi-target candidate is whether the crude stage can be made good enough that purification does not become economically prohibitive.
The supply chain context comes from GenScript, which reports GMP manufacturing support for IND applications through phase II at scales from milligrams to kilograms, a peptide synthesis success rate of approximately 99%, and an order completion rate of approximately 99%. Those statements are vendor-reported and are not independently verified; the material describing them is promotional in nature. The tirzepatide yield and purity figures come from the cited Eli Lilly report, which is likewise not reproduced in full, so the experimental details cannot be checked against it.
ClinicalTrials.gov, operated by the U.S. National Library of Medicine and the National Institutes of Health, is the public index for the trials these drugs are running, and the file at Peptide Atlas shows how far the class has spread. Semaglutide has 668 registered clinical trials on file, 10 of them currently recruiting; among trials with a phase annotation, 4 are Phase 2, 4 are Phase 4, and 1 is Phase 3. Recent registrations include a Phase 2 trial for stage 1 type 1 diabetes NCT07430332 , a Phase 2 beta-cell preservation trial in recent-onset type 1 diabetes NCT07614412 , a Phase 4 pre-surgical optimization trial in obesity and early-stage endometrial cancer NCT07462663 , a Phase 4 trial of metabolic surgery for atrial fibrillation elimination in obesity NCT07027969 , a Phase 4 weight-management trial in childhood obesity NCT06977438 , and a trial pairing GLP-1 therapy with lifestyle interventions for severe mental illness NCT07586150 .
Tirzepatide has 251 registered clinical trials on file, also 10 currently recruiting; the phase annotations include 5 Phase 2, 2 Phase 4, and 1 Phase 3. Its registrations reach into type 1 diabetes with overweight or obesity NCT06180616 , cannabis use disorder NCT07468552 , atrial fibrillation recurrence after catheter ablation in patients with obesity and heart failure with preserved ejection fraction NCT07630454 , skeletal muscle quality under dual agonist therapy plus structured exercise…
Peptides referenced: Semaglutide, Tirzepatide, Liraglutide, Cagrilintide, Exenatide, Dulaglutide, Lixisenatide, Albiglutide.
Vendors referenced: Genscript.
Related reading: FDA Panel Backs Six Unapproved Peptides for 503A Compounding List, GenScript maps three delivery routes for neoantigen vaccines, Cyclized Cecropin A Peptide Reaches Phase IIa for CRAB Pneumonia, Zero FDA Approvals: The Translational Puzzle of Cell-Penetrating Peptides.